EI
AMLX icon

EAM Investors’s Amylyx Pharmaceuticals AMLX Stock Holding History

EAM Investors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-53,256
Closed -$740K – 272
2026
Q1 		$740K Hold
53,256
– – 0.09% 236
2025
Q4 		$643K Sell
53,256
-21,855
-29% -$297K 0.07% 246
2025
Q3 		$1.02M Sell
75,111
-24,849
-25% -$234K 0.12% 191
2025
Q2 		$641K Buy
+99,960
New +$486K 0.1% 197
2023
Q1 		– Sell
-65,272
Closed -$2.41M – 252
2022
Q4 		$2.41M Buy
+65,272
New +$2.32M 0.5% 64

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

EAM Investors's AMLX Position: Q2 2026 in Review

EAM Investors sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2026, closing a stake of 53,256 shares — an estimated $740K sold.

EAM Investors first reported a position in AMLX in Q4 2022 and held it in 5 quarters. The position peaked at $2.41M in Q4 2022. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • EAM Investors reported no remaining Amylyx Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • EAM Investors sold 53,256 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $740K.
  • EAM Investors first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • EAM Investors's Amylyx Pharmaceuticals position peaked at $2.41M in Q4 2022.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.